跳至主要内容
临床试验/NCT05349825
NCT05349825已完成不适用

Investigation of MDR1 (Multi-Drug Resistance) Gene Polymorphism and Losartan Plasma Concentration in Patients Undergoing Hypertensive Episodes While Under Losartan Treatment: A Prospective, Case-Control Study

Pamukkale University1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2017年10月23日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
100
试验地点
1
主要终点
MDR1 gene polimorphism does not influence losartan consantration nevertheless changes blood pressure lowering effect of losartan

研究概览

简要总结

Losartan is an antihypertensive drug belonging to the ARB family. It is characterized as the substrate of the Multi Drug Resistance-1 (MDR1) drug-efflux protein (a pump that ensures the removal of drugs/foreign substances out of the cell) encoded by the ATP Binding Cassette Subfamily B Member 1 (ABCB1) gene. A recent line of evidence indicates that potential polymorphisms in this gene tend to alter the absorption, transport, bioavailability of losartan, and, indirectly, its effectiveness in hypertension control. As identified by new research, the C3435T, G2677T, and C1236T polymorphic alleles of the MDR1 gene might alter the bioavailability and thus the effectiveness of losartan

详细描述

This trial was conducted in the emergency services of Gazi University and Pamukkale University. The patient group was comprised of 50 individuals presenting with a hypertensive episode (patients under 60, >140/90 mmHg, patients over 60, >150/90 mmHg, according to the JNC8 guidelines) while under losartan treatment. The control group, by contrast, included 50 patients whose blood pressure was regulated while receiving losartan treatment and who were admitted to the ED for reasons other than hypertensive episode. The eligible patients matching the inclusion and exclusion criteria were recruited for the study.

Within the scope of this research, we included hypertension patients over 18 who gave their informed consent for the study and received minimum 25 mg losartan daily for at least six weeks. 50 individuals admitted to the ED due to a hypertensive episode while under losartan treatment were assigned to the patient group, while 50 patients whose blood pressure was regulated while receiving losartan treatment and who were admitted to the ED for reasons other than hypertensive episode were included in the control group. Those who did not give their consent to participate and did not match the inclusion criteria were excluded from the scope of the study Prior to the trial, the participants were assessed based on the pre-defined patient selection criteria, and the non-eligible ones were excluded from the trial. These exclusion criteria can be listed as refusal to participate in the study, illiteracy, being under 18, being pregnant and in lactation period, being hemodynamically unstable (mean arterial pressure <65mmHg), undergoing kidney transplantation, having liver failure (CHILD PUGH Class C and higher patients) or renal failure (GFR<60), and taking anti-hypertensive drugs other than losartan(Figure 1).

Initially, 20 ml of blood was collected from the enrolled patients. 10 ml of blood was stored in the tubes with ethylene diamine tetraacetic acid (EDTA) until Deoxyribonucleic acid (DNA) isolation was performed at -20 degrees and plasma level was identified. The remaining 10 ml was centrifuged at 3500 rpm for 10 min, and the plasma was separated. The resulting plasmas were stored in the eppendorf tubes at -20°C until the tandem mass spectrometry measurement.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Cross Sectional

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • gave their informed consent
  • received minimum 25 mg losartan daily for at least six weeks

排除标准

  • refusal to participate in the study
  • illiteracy
  • pregnant or in lactation period
  • hemodynamically unstable (mean arterial pressure <65mmHg)
  • kidney transplantation
  • liver failure (CHILD PUGH Class C and higher patients) or renal failure (GFR<60)
  • taking anti-hypertensive drugs other than losartan

结局指标

主要结局

MDR1 gene polimorphism does not influence losartan consantration nevertheless changes blood pressure lowering effect of losartan

时间窗: at least six weeks under losartan treatment

50 patients receiving anti-hypertensive treatment with losartan, presenting to the ED with a hypertensive episode and 50 patients whose blood pressure was regulated while receiving losartan treatment and who presented to the ED for reasons other than hypertensive episode. Compare two groups losartan consantration and MDR1 gene polymorphyms

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Üzeyir Çimen

Research Assistant

Pamukkale University

研究点 (1)

Loading locations...

相似试验